Cargando…

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly haematologic. Since preclinical data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelderblom, H, Sparreboom, A, Jonge, M J A de, Loos, W J, Wilms, E, Mantel, M A, Hennis, B, Camlett, I, Verweij, J, Burg, M E L van der
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375148/ https://www.ncbi.nlm.nih.gov/pubmed/11710824 http://dx.doi.org/10.1054/bjoc.2001.2014

Ejemplares similares

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix
por: Wit, R de, et al.
Publicado: (1999)

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study
por: Frasci, G, et al.
Publicado: (2001)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
por: Awada, A, et al.
Publicado: (1999)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
por: Planting, A. S., et al.
Publicado: (1993)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Phase II Study to Topotecan and Cisplatin in Advanced Hepatocellular Carcinoma
por: Lee, Ga Young, et al.
Publicado: (2003)

New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines
por: Świerczewska, Monika, et al.
Publicado: (2017)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
por: Vanhoefer, U, et al.
Publicado: (1999)

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma
por: Mulatero, C, et al.
Publicado: (2000)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.
por: Planting, A. S., et al.
Publicado: (1996)

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy
por: de Wit, R, et al.
Publicado: (2001)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
por: Gaast, A van der, et al.
Publicado: (1999)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
por: de Jongh, F E, et al.
Publicado: (2003)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
por: Watanabe, Y, et al.
Publicado: (2001)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study
por: Hong, R L, et al.
Publicado: (1999)

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
por: Schuyer, M, et al.
Publicado: (2001)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gueb3odt5m815bviv526mj6rim